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Background. Leptin, a recently discovered peptide involved in
nutrient intake and energy expenditure, has been shown to be
abnormally regulated in certain conditions such as obesity. In
chronic renal failure, leptin appears to be increased. However,
little is known about leptin regulation during chronic renal failure
(CRF).
Methods. We measured serum leptin in eight well nourished,
chronic hemodialysis patients (seven males, one female) receiving
anabolic factors for three days as either recombinant insulin-like
growth factor-1 (rhIGF-1) or a combination of recombinant
growth hormone (rhGH) plus recombinant IGF-1, in a random
cross-over trial.
Results. Serum leptin values were in the range of normal
volunteers matched for body mass index. As reported in other
conditions, serum leptin was strongly correlated with patients dry
body wt (P 5 0.01) and body fat (P 5 0.0001). Both treatments
affected serum leptin in a rapid and opposite manner. RhIGF-1
decreased serum leptin from 11.2 6 20.8 (SD) to 4.3 6 3.8 mg/liter
(P 5 0.011), whereas the combination of rhGH 1 rhIGF-1
increased serum leptin from 7.4 6 9.4 to 21.0 6 32.9 mg/liter (P 5
0.011). Regression analyses indicated a linear regression between
serum leptin and insulin variations after treatment.
Conclusions. This study shows for the first time that both
rhIGF-1 and rhGH acutely regulate serum leptin in dialysis
patients. Whether leptin changes are explained by the concomi-
tant insulin variation should be further studied under renal failure
conditions.
Recently, the ob gene product, a 16 kD peptide called
leptin, was identified from obese mice [1]. Deletion muta-
tion of this gene leads to absence of circulating leptin,
whereas administration of recombinant leptin strongly re-
duces food intake and induces a rapid weight loss in lean
and obese mice [2–4]. The site of action of leptin is mainly
thought to be the hypothalamic appetite center [5, 6],
although leptin receptors have now been reported in pan-
creas, liver and kidney [7–9]. Clinical studies have shown
that obese patients present high circulating levels of leptin
suggesting a resistance to the action of leptin [10]. Some
data suggest that this resistance may be peripheral [11],
whereas other recent studies involve leptin binding to
specific circulating proteins [12] as well as abnormal cross-
ing of leptin through the blood brain barrier [5].
Because chronic renal failure patients often present
moderate to severe malnutrition and reduced food intake,
it seemed of interest to characterize the regulation of this
compound in end-stage renal disease patients undergoing
chonic dialysis therapy. We designed a study to measure the
metabolic effects of recombinant growth factors in dialysis
patients, and therefore had the opportunity to measure
serum leptin and the regulatory effects of insulin-like
growth factor (IGF)-1 and growth hormone (GH) on serum
leptin in those individuals.
METHODS
Patients
Eight well nourished, chronically hemodialyzed patients
(seven males, one female; Table 1) were enrolled in a
metabolic study after an informed signed consent approved
by the consultative committee for biomedical research at
Lyon. These patients had been treated by chronic hemodi-
alysis for at least four months prior to the study. There was
no acute or chronic inflammatory process and patients did
not take any glucocorticoids or insulin the last eight weeks
before and during the study. Two patients were on regular
erythropoietin treatment that was not modified during the
study. They were under regular antihypertensive treatment
when needed and oral calcium supplements. The patients’
usual diet was assessed from a dietary interview at inclu-
sion, and was kept constant during hospital stays (Table 1).
1 See Editorial by Dagogo-Jack, p. 997.
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Patients were asked to remain for four days in a meta-
bolic ward on two occasions that were separated by 14 to 28
days. During these stays, they underwent a daily blood
drawn and two metabolic studies, one on the first (D1) and
the second on the fourth day (D4). In order to keep
metabolic conditions as stable as possible, patients under-
went their routine dialysis sessions on day 0, day 2 (after-
noon) and day 4 (evening).
Anthropometry
Anthropometry was collected once for each patient at
enrollment in the study. Measurements included the deter-
mination of actual body weight corrresponding to the dry
weight of patients, that is, the lowest weight obtained at the
end of their regular dialysis session. Relative body wt
(RBW) was expressed as the ratio of patient dry weight by
standard body wt as determined by Metropolitan Insurance
tables [13]. Skinfold thickness measurements were per-
formed in triplicate at four different locations: biccipital,
tricipital, subscapular and suprailiac. Fat mass was deter-
mined from the Durnin and Wormseley tables [14].
Treatment
The study was designed to compare the effects of either
recombinant human (rh)IGF-1 administration alone (40
mg/kg body wt every 12 hr) or a combination of rhIGF-1 (40
mg/kg body wt every 12 hr) and recombinant human growth
hormone, rhGH (Genotonorm®; 50 mg/kg body wt per
day). Treatments were administered subcutaneously in the
anterior quadrant of the quadriceps at 8:00 a.m. (rhIGF-1)
and 8:00 p.m. (rhIGF-1 and rhGH). Both recombinant
hormones were generously provided by Pharmacia and
Upjohn, Sweden.
Serum measurements
Blood was drawn at 7:45 a.m. before breakfast and after
a 10 hour overnight fast. Samples were immediately chilled
on ice. After clotting, samples were centrifuged at 3000 g at
4°C for 10 minutes and serum was then pipetted for
conservation at 270°C until measurements.
Serum leptin was measured in duplicate by RIA (Linco
Research, St. Louis, MO, USA) as previously described
[10]. The sensitivity of assay was 0.5 ng/ml. Intra- and
interassay coefficient of variation were 6.2 and 8.3%,
respectively. Normal serum leptin values in our laboratory
were 11.0 6 (SD)4.9 and 5.1 6 3.3 ng/ml in female and male,
respectively. Serum leptin values for adult patients under-
going routine hemodialysis in our unit were found to be
16.7 6 17.8 and 12.6 6 11.4 ng/ml in female (N 5 23) and
male (N 5 23), respectively.
Serum IGF-1 was measured by RIA using a rabbit
antibody after acid-ethanol extraction and cryoprecipita-
tion as previously described [15] in order to eliminate the
IGF binding protein degradation products often present in
chronic renal failure. Adult normal serum IGF-1 values
were 283 6 77 mg/liter. Serum GH was measured by
immunoradiometric assay using a mouse monoclonal anti-
body (BioMe´rieux, Marcy l’Etoile, France). The GH assay
limit of detection was 0.16 mg/liter. Intra- and interassay
coefficient of variation were 5.2 and 6.0%, respectively.
Serum insulin was measured by immunoradiometric assay
using a mouse monoclonal antibody (ERIA Diagnostics
Pasteur, Marnes la Coquette, France). The insulin assay
limit of detection was 0.2 mU/liter. Intra- and interassay
coefficient of variation were 3.8 and 7.5%, respectively.
Statistics
The paired t-test and Wilcoxon rank test were performed
for comparisons between final and baseline values or
percentage variations from baseline when applicable, and
for between treatment comparisons. For correlation search
between baseline serum values (that is, insulin, IGF-1, GH
and leptin) and various parameters, the mean of the two
baseline measures was used. Statview software (Abacus
concept, CA, USA) was used on a Macintosh computer. A
P value less than 0.05 was considered significant.
RESULTS
Table 1 shows the characteristics of patients. Relative
body weigth (RBW) was greater than 90% of standard body
wt. None of them were obese or malnourished as assessed
by actual body wt, serum albumin or body mass index
(BMI). However, one male patient was at the upper normal
limit, had a BMI of 25.5, a RBW of 106% and a fat mass of
24.3%. His baseline serum leptin and insulin values were
46.2 ng/ml and 13.9 mU/liter, respectively. The only woman
in this study had a BMI of 18.8 kg/m2 and a fat mass of
23.0%. Her serum leptin and insulin values were 7.8 ng/ml
and 3.8 mU/liter, respectively. Otherwise, these two pa-
tients responded equally to the treatments, expressing
similar changes to those of the remaining men and there-
fore were kept for final analysis.
Serum hormones appear on Table 2. Baseline values for
all parameters (D1) were not different for the two basal
measurements separated by 14 to 28 days. Mean basal
Table 1. Characteristics of the subjects
Age year 41.6 6 12.1
Sex ratio (M/F) 7/1
Dialysis treatment duration months 30.1 6 23.9
Range 4–74
Actual body weight kga 63.7 6 13.2
Relative body weight %b 95 6 7
Serum albumin g/liter 45.5 6 3.2
Body Mass Index 21.6 6 2.2
Body fat % 16.1 6 5.0
Lean body mass kg 53.3 6 9.9
Energy intake kcal/kg per day 36.2 6 7.8
Protein intake g/kg per day 1.40 6 0.27
Values are expressed as mean 6 SD.
a As dry body weight at the end of the last hemodialysis treatment
preceding the first treatment period
b Relative body weight, calculated from [13]
Fouque et al: Leptin regulation in dialysis patients 933
concentrations of serum leptin were 10.1 6 17.7 ng/ml in
males and 7.7 ng/ml in the female patient and were not
different from normal adults (5.1 6 3.3 in males and 11.0 6
4.9 ng/ml in females, N 5 27). Serum IGF-1 and GH values
were in the range of normal adults (Table 2). Serum insulin
were in the range of fasting healthy adults for the seven
lean patients (5.0 6 2.2 mU/liter), whereas it was markedly
elevated in the borderline overweight patient (13.9 mU/
liter).
As recently described in dialysis patients [16], we found
statistical correlations by linear regression between base-
line leptin and body wt (r 5 0.82, P 5 0.012), BMI (r 5
0.72, P 5 0.047), percent of body fat mass (r 5 0.74, P 5
0.03) and most significant between leptin and absolute fat
mass (r 5 0.99, P 5 0.0001; Fig. 1). When the borderline
overweight patient was not considered for analysis, the
regression between leptin and weight or BMI lost its
significance, but was still robust between leptin and percent
of body fat mass (r 5 0.82, P 5 0.025, N 5 7) or absolute
fat mass (r 5 0.85, P 5 0.014, N 5 7).
After a three-day rhIGF-1 treatment (40 mg/kg body wt
every 12 hr, total of 5 injections), serum IGF-1 values
increased by 103% (P 5 0.011 from baseline; Table 2).
When patients received the rhIGF-1 1 rhGH treatment
(40 mg/kg rhIGF-1 every 12 hr, total of 5 injections and 50
mg/kg rhGH per day, total of 3 injections), serum IGF-1
increased by 317% from baseline (P 5 0.01). The incre-
ment in serum IGF-1 under the rhIGF-1 1 rhGH combi-
nation appeared to become statistically different from the
IGF-1 treatment alone at day 3 (data not shown). Serum
GH levels increased during the combination of rhIGF-1 1
rhGH (P 5 0.011 from baseline), whereas they tend to
decrease under rhIGF-1 treatment alone (P 5 0.12, NS).
The values for serum leptin were statistically modified
from baseline by each treatment. Recombinant IGF-1
administration decreased serum leptin levels by 25 6 26%
from baseline (P 5 0.025), whereas the combination of
rhIGF-1 1 rhGH increased fasting serum leptin by 117 6
91% from baseline (P 5 0.009; Fig. 2). Serum insulin was
also markedly altered by both treatments. Under rhIGF-1
alone, fasting insulin decreased to 3.6 6 2.9 mU/liter (P 5
0.011; Table 2). On the contrary, under rhGH 1 rhIGF-1
treatment, the serum levels of insulin markedly increased to
33.6 6 51.9 mU/liter, that is, by a magnitude of five as
compared to baseline (P 5 0.011; Table 2).
The effects of growth factors on leptin regulation may be
assessed from the relationship between the variation in
serum leptin and the concomitant change in other serum
values after treatment at D4. Figure 3 plots the change in
serum leptin versus the change in serum insulin during
treatment. All baseline leptin values were modified in a
similar pattern, that is, the leptin value increased when
serum insulin rose under the combined rhIGF-1 1 rhGH
treatment, whereas serum leptin decreased when serum
insulin was blunted under rhIGF-1 treatment alone (Fig.
3). There was a strong, statistically significant correlation
between the change in serum leptin and the concomitant
change in serum insulin (r 5 0.66, P 5 0.006, Fig. 3). If the
borderline overweight patient was not considered for anal-
ysis, this relationship was still significant (r 5 0.58, P 5
0.029).
Fig. 1. The linear regression between fat mass as estimated by skinfold
thicknesses, and fasting serum leptin of eight well nourished, mainte-
nance dialysis patients (r 5 0.99, P 5 0.0001).
Table 2. Serum hormones values before and after three days of treatmenta
Treatment
rhIGF-1 80 mg/kg/day/3 days (rhIGF-1 80 mg/kg 1 rhGH 50 mg/kg)/day/3 days
Baseline Day 4 Baseline Day 4
Leptin mg/liter 11.2 6 20.8 4.3 6 3.8b 7.4 6 9.4 21.0 6 32.9b,c
Insulin mU/liter 6.5 6 4.9 3.6 6 2.9b 5.8 6 3.0 33.6 6 51.9b,c
Growth hormone mg/liter 3.4 6 4.8 1.5 6 1.6 2.1 6 1.7 12.3 6 3.9b,c
IGF-1 mg/liter 355 6 164 706 6 294b 357 6 144 1399 6 491b,c
a Values are mean 6 SD. Eight subjects were studied under both rhIGF-1 treatment or rhIGF-1 1 rhGH treatment in a random order.
b Differs from the corresponding baseline value: P , 0.025
c Differs from rhIGF-1 treatment: P , 0.025, Wilcoxon rank test
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Comparable analyses were performed for serum growth
hormone and serum IGF-1 values. However, no significant
relationship was found between these latter values and
serum leptin. In addition, we did not found any relationship
between baseline serum leptin (D1) and either baseline
serum free fatty acids, serum total cholesterol or serum
triglycerides (data not shown), nor was any relationship
observed between the absolute or percentage change in
these values after any treatment.
DISCUSSION
Malnutrition is a common feature in end-stage renal
disease [17–19]. Anorexia has been commonly reported in
these patients, and despite intense counseling from the
staff, patients often fail to increase their food intake. A
number of reports have shown that it is not uncommon to
record energy intake as low as 23 to 25 kcal/kg body wt/day
in maintenance hemodialysis patients [20]. Furthermore,
this spontaneous reduction in food intake may appear
before end-stage renal disease, and two studies reported a
linear energy and protein intake decrease with the decline
of renal function over time [21, 22].
Recently, a new peptide affecting food intake, named
leptin, has been discovered [1], and due to renal failure its
synthesis or clearance may be impaired. Serum leptin has
been reported to be elevated in patients with pre-dialysis
chronic renal failure [23, 24] and undergoing chronic hemo-
or peritoneal dialysis [16, 25–27]. Although the kidney is
responsible for about 80% of leptin clearance in healthy
adults [28], little is known on the fate of leptin in chronic
renal failure patients. Stenvinkel, Heimbu¨rger and
Lonnqvist recently pointed out that dialysis patients with
high serum leptin could be separated from those with
normal leptin based on their fasting serum insulin [24]. We
had the opportunity to measure this peptide during meta-
bolic studies in well nourished, non-obese maintenance
hemodialysis patients and looked at the potential role of
two other peptide hormones, growth hormone and IGF-1,
in altering the leptin status in eight well nourished, non-
obese maintenance dialysis patients.
The leptin values we report here are within the normal
range of healthy volunteers matched for gender and body
mass index. To further clarify this unexpected finding, we
looked at other parameters in these lean patients. Interest-
ingly, like Stenvinkel et al [24], we found that the present
patients, except one, had low to normal fasting serum
insulin levels and their leptin values were in the normal
range. On the contrary, the borderline overweight patient
had elevated fasting leptin and insulin values (46.2 ng/ml
and 13.9 mU/liter, respectively), confirming the threshold
insulin value of about 14 mU/liter reported by Stenvinkel et
al for elevated leptin in pre-dialysis CRF patients [24].
The relationship between serum leptin and body compo-
sition in dialysis patients have been precisely documented
in a recent report by Heimbu¨rger et al [16]. Although we
used a different method for estimating body fat mass
(skinfold thickness measurement), the present results (Fig.
1) confirm Heimbu¨rger’s findings, showing a strong rela-
tionship between body fat, that is, percent body fat, total
body fat and BMI, and leptin, giving strength to the role of
leptin as a marker of body composition during maintenance
hemodialysis [16]. This relationship is still present in a
limited range of body fat values if the bigger patient is
removed from analysis (r 5 0.85, P 5 0.01), and also nicely
Fig. 2. The percent change from baseline of serum leptin in eight
maintenance hemodialysis patients after a three-day treatment of either
rhIGF-1 or a combination of rhIGF-1 1 rhGH administered in a random
order, separated by 14 to 28 days (*P 5 0.025 vs. baseline; †P < 0.01 vs.
baseline and vs. rhIGF-1 alone).
Fig. 3. The linear regression between the percent change from baseline in
serum leptin and the concomitant serum insulin variation after treatment
(r 5 0.66, P 5 0.006).
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confirmed in end-stage renal disease patients having ele-
vated fat mass as high as 40 to 50% body wt [16].
Factors regulating serum leptin in dialysis patients
Leptin is acutely regulated by peptidic hormones in
end-stage renal disease patients. Indeed, increasing serum
IGF-1 values by a magnitude of two after administering
rhIGF-1 during three days lowered serum leptin by about
25% (P , 0.03; Fig. 2). Since adipocytes are sensitive to
IGF-1 [29], the administration of exogenous rhIGF-1 may
directly reduce the adipocyte leptin release. This hypothesis
cannot be confirmed due to the lack of experimental data.
On the other hand, because IGF-1 induces a negative
feedback on GH secretion [30], one may argue that the
observed leptin drop may be secondary to the GH decrease
under rhIGF-1 treatment. We did not observe a significant
decrease in serum GH, since GH fell in five patients and
either did not change or increased in the other three
patients. In addition, no significant correlation was found
between the decrease in serum leptin and serum GH.
The addition of rhGH to rhIGF-1 not only prevented the
IGF-1-induced serum leptin decrease, but actually in-
creased leptin values in all patients (P 5 0.011, Fig. 2).
Thus, rhGH may have had an independant effect on leptin
release, as reported by Bianda and colleagues in eight adult
GH-deficient patients without renal failure [31]. Over the
long-term, this fact may be attributed to GH-induced
changes in body composition (increase in body wt, serum
insulin and appetite). However, during short-term meta-
bolic studies, changes in body composition are unlikely to
occur and the actual results are in line with those of Bianda
et al, convincingly showing an increase in serum leptin
during a short-term rhGH treatment [31].
A number of experimental in vitro and in vivo studies
have shown that insulin regulates adipocyte leptin secretion
[32, 33]. In humans, a prolonged exposition to insulin
increased serum leptin, whereas a five hour insulin admin-
istration did not change the serum leptin value [32]. In
insulin resistant states, increased serum leptin levels have
been reported [34]. Since an insulin resistant state is often
present in ESRD patients, an impaired leptin status may be
present.
The linear regression observed on Figure 3 suggests a
potential regulatory effect of insulin on leptin secretion
after three days of treatment, since no correlation was
found between leptin and either GH or IGF-1 levels, or
between their concomitant changes after treatment. When
rhIGF-1 was administered alone, serum leptin significantly
decreased, and was significantly related to the serum insulin
decrease. The only other study that reports the actions of
rhIGF-1 on leptin in human showed a 48 hour delay
between the decrease in C-peptide and serum leptin [31],
which is not in favor of an acute insulin regulation of leptin
secretion. Since we did not measure leptin daily, we cannot
confirm the fact that insulin acutely blunts the leptin
release. However, at 72 hours, it is worthwhile to emphasize
the relationship between serum leptin and serum insulin in
MHD patients.
The addition of rhGH to rhIGF-1 increased serum leptin
and insulin values (Table 2). This GH effect not only
surpassed the IGF-1-induced leptin reduction, but actually
increased the serum leptin by a magnitude of two. Con-
comitantly, serum insulin dramatically rose in all patients, a
well described consequence of an acute rhGH administra-
tion. Since we did not directly administer insulin, we cannot
clearly identify the GH effect from that of insulin on leptin
release. However, in support of a delayed insulin regulation
of leptin release, Boden et al recently showed in healthy
adults that a constant insulin administration did increase
serum leptin in a dose-dependant manner after 24 hours of
infusion and was sustained during the rest of the 72 hour
study [35]. In an in vitro study, Bo¨ni-Schnetzler et al showed
that administering rhGH for six days to hypophysectomized
rats did not increase adipocyte leptin mRNA [36]. Inter-
estingly, these authors did not observe an increase in serum
insulin in the rhGH treated group of rats. Although the
acute regulation of leptin mRNA may not reflect the serum
leptin profile, it is possible that, in order to observe a
GH-induced leptin release, an increase in serum insulin
should have occurred [36].
In conclusion, according to the available research data
and the present study, serum leptin appears to be a reliable
index of body fat in end-stage renal disease. Elevated
values may be seen in patients with insulin resistance
and/or elevated fasting serum insulin, whereas normal
values are often present in lean CRF patients with low
serum insulin values. Administering recombinant hor-
mones such as growth hormone and IGF-1 modify serum
leptin, suggesting that there is a conserved metabolic
regulation of leptin production in end-stage renal disease.
Whether these changes are directly caused by rhIGF-1 and
rhGH or the concomitant insulin changes remain to be
clarified in the dialysis condition. Furthermore, the role of
insulin on leptin accumulation should also be studied, since
treatments may worsen insulin resistance and lead to more
elevated serum leptin levels and a potential anorectic
status.
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